Bernhardt G. Zeiher, M.D., FACP, FCCP, began serving as director of Amylyx in 2024. Dr. Zeiher has more than 20 years of experience in the pharmaceutical industry with expertise in drug development. He is a member of the Board of Directors at Entrada Therapeutics and most recently served as Chief Medical Officer (CMO) of Astellas Pharma from 2018 to 2022. As CMO, Dr. Zeiher led the development of early and late-stage therapies, medical and regulatory affairs, pharmacovigilance, and quality assurance for an organization of nearly 3,000 global employees. His time overseeing Astellas’ development sector was the most productive period in the company’s history, with approvals for Cresemba®, Xtandi®, Xospata®, Padcev® and Evrenzo®, as well as the acquisition submission of VEOZAHTM (fezolinetant), which was approved by the FDA in May 2023. Prior to his time at Astellas, Dr. Zeiher held various roles leading drug development at other pharmaceutical companies including Pfizer, Eli Lilly and Company, and Merck, and he also practiced medicine at a tertiary medical center in Indianapolis upon completing his physician training.
Dr. Zeiher, fellow of the American College of Physicians and the American College of Chest Physicians, received a B.S. in Biology from the University of Toledo and an M.D. from Case Western Reserve University School of Medicine. He also completed his internal medicine residency and chief residency at the University Hospitals of Cleveland and did a fellowship in Pulmonary and Critical Care Medicine at the University of Iowa Hospitals and Clinics.
What is Bernhardt G. Zeiher's net worth?
The estimated net worth of Bernhardt G. Zeiher is at least $144.90 thousand as of March 20th, 2025. Zeiher owns 10,000 shares of Amylyx Pharmaceuticals stock worth more than $144,900 as of December 5th. This net worth evaluation does not reflect any other investments that Zeiher may own. Learn More about Bernhardt G. Zeiher's net worth.
How do I contact Bernhardt G. Zeiher?
Has Bernhardt G. Zeiher been buying or selling shares of Amylyx Pharmaceuticals?
Bernhardt G. Zeiher has not been actively trading shares of Amylyx Pharmaceuticals during the past quarter. Most recently, on Thursday, March 20th, Bernhardt G. Zeiher bought 10,000 shares of Amylyx Pharmaceuticals stock. The stock was acquired at an average cost of $3.70 per share, with a total value of $37,000.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $37,000. Learn More on Bernhardt G. Zeiher's trading history.
Who are Amylyx Pharmaceuticals' active insiders?
Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amylyx Pharmaceuticals?
In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $37,000.00. In the last year, insiders at the sold shares 13 times. They sold a total of 169,893 shares worth more than $1,666,686.16. The most recent insider tranaction occured on December, 1st when insider Camille L Bedrosian sold 6,580 shares worth more than $94,423.00. Insiders at Amylyx Pharmaceuticals own 12.3% of the company.
Learn More about insider trades at Amylyx Pharmaceuticals. Information on this page was last updated on 12/1/2025.
